Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

The interferon response inhibits HIV particle production by induction of TRIM22.

Barr SD, Smiley JR, Bushman FD.

PLoS Pathog. 2008 Feb 29;4(2):e1000007. doi: 10.1371/journal.ppat.1000007.

2.

Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection.

Singh R, Gaiha G, Werner L, McKim K, Mlisana K, Luban J, Walker BD, Karim SS, Brass AL, Ndung'u T; CAPRISA Acute Infection Study Team.

J Virol. 2011 Jan;85(1):208-16. doi: 10.1128/JVI.01810-10. Epub 2010 Oct 27.

3.

TRIM5α and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment.

Singh R, Patel V, Mureithi MW, Naranbhai V, Ramsuran D, Tulsi S, Hiramen K, Werner L, Mlisana K, Altfeld M, Luban J, Kasprowicz V, Dheda K, Abdool Karim SS, Ndung'u T.

J Virol. 2014 Apr;88(8):4291-303. doi: 10.1128/JVI.03603-13. Epub 2014 Jan 29.

4.
5.

Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15.

Okumura A, Lu G, Pitha-Rowe I, Pitha PM.

Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1440-5. Epub 2006 Jan 24.

6.

HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane.

Neil SJ, Eastman SW, Jouvenet N, Bieniasz PD.

PLoS Pathog. 2006 May;2(5):e39. Epub 2006 May 12.

7.

TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements.

Kajaste-Rudnitski A, Marelli SS, Pultrone C, Pertel T, Uchil PD, Mechti N, Mothes W, Poli G, Luban J, Vicenzi E.

J Virol. 2011 May;85(10):5183-96. doi: 10.1128/JVI.02302-10. Epub 2011 Feb 23.

8.

Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Neil SJ, Zang T, Bieniasz PD.

Nature. 2008 Jan 24;451(7177):425-30. doi: 10.1038/nature06553. Epub 2008 Jan 16.

PMID:
18200009
10.

The C-terminal portion of the Hrs protein interacts with Tsg101 and interferes with human immunodeficiency virus type 1 Gag particle production.

Bouamr F, Houck-Loomis BR, De Los Santos M, Casaday RJ, Johnson MC, Goff SP.

J Virol. 2007 Mar;81(6):2909-22. Epub 2006 Dec 20.

11.

Late domain-dependent inhibition of equine infectious anemia virus budding.

Shehu-Xhilaga M, Ablan S, Demirov DG, Chen C, Montelaro RC, Freed EO.

J Virol. 2004 Jan;78(2):724-32.

12.

Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

Sei S, Yang QE, O'Neill D, Yoshimura K, Nagashima K, Mitsuya H.

J Virol. 2000 May;74(10):4621-33.

13.

Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression.

Goila-Gaur R, Demirov DG, Orenstein JM, Ono A, Freed EO.

J Virol. 2003 Jun;77(11):6507-19.

15.
16.

The interaction between HIV-1 Gag and APOBEC3G.

Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L.

J Biol Chem. 2004 Aug 6;279(32):33177-84. Epub 2004 May 24.

17.
18.

Inhibition of human immunodeficiency virus type 1 morphogenesis in T cells by alpha interferon.

Smith MS, Thresher RJ, Pagano JS.

Antimicrob Agents Chemother. 1991 Jan;35(1):62-7.

19.

Human HERC5 restricts an early stage of HIV-1 assembly by a mechanism correlating with the ISGylation of Gag.

Woods MW, Kelly JN, Hattlmann CJ, Tong JG, Xu LS, Coleman MD, Quest GR, Smiley JR, Barr SD.

Retrovirology. 2011 Nov 17;8:95. doi: 10.1186/1742-4690-8-95.

20.

The host cell MAP kinase ERK-2 regulates viral assembly and release by phosphorylating the p6gag protein of HIV-1.

Hemonnot B, Cartier C, Gay B, Rebuffat S, Bardy M, Devaux C, Boyer V, Briant L.

J Biol Chem. 2004 Jul 30;279(31):32426-34. Epub 2004 May 21.

Items per page

Supplemental Content

Write to the Help Desk